Joshua Hansen

USPTO Granted Patents = 39 (Patent Applications = 15)

CIPO Patents = 1 (Patent Applications = 5)

EPO Patents = 12 (Patent Applications = 18)

Average Co-Inventor Count = 9.5

ph-index = 8

Forward Citations = 207(Granted Patents)

Location History:

La Jolla, CA (US) (2015 - 2024)
San Diego, CA (US) (2021 - 2024)

Company Filing History:

Signal Pharmaceuticals, Inc.

patents

1 out of 3,681

Bristol-myers Squibb Compnay

patents

Years Active: 2015-2025

Loading Chart...

39 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12486281 - Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith (2025-12-02),

2. 12404241 - Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith (2025-09-02),

3. 12227490 - Cereblon binding compounds, compositions thereof, and methods of treatment therewith (2025-02-18),

4. 12187699 - GSPT1 compounds and methods of use of the novel compounds (2025-01-07),

5. 12103920 - Cereblon binding compounds, compositions thereof, and methods of treatment therewith (2024-10-01),

6. 12029738 - Antiproliferative compounds and methods of use thereof (2024-07-09),

7. 11945804 - Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith (2024-04-02),

8. 11873283 - Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith (2024-01-16),

9. 11739075 - Cereblon binding compounds, compositions thereof, and methods of treatment therewith (2023-08-29),

10. 11726080 - Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile (2023-08-15),

11. 11634407 - Cereblon binding compounds, compositions thereof, and methods of treatment therewith (2023-04-25),

12. 11590139 - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith (2023-02-28),

13. 11560371 - Cereblon binding compounds, compositions thereof, and methods of treatment therewith (2023-01-24),

14. 11365184 - Antiproliferative compounds, and their pharmaceutical compositions and uses (2022-06-21),

15. 11358952 - Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith (2022-06-14),

Joshua Hansen: A Pioneer in Therapeutic Compounds

Introduction. Joshua Hansen, based in La Jolla, California, has made a significant impact in the field of pharmaceuticals and biochemistry. With an impressive portfolio of 36 patents, his innovations focus primarily on compounds that target and modify biological processes, particularly in the treatment of diseases linked to the androgen receptor.

Latest Patents. Among his latest intellectual contributions are several patents for Cereblon binding compounds and compositions, which include piperidine dione compounds designed to treat or prevent androgen receptor-mediated diseases. These innovative compounds demonstrate a unique structure characterized by specific groups and configurations, aimed at enhancing therapeutic efficacy.

Career Highlights. Hansen has built a distinguished career, working with prestigious organizations such as Celgene Corporation and Signal Pharmaceuticals, Inc. His work in these companies has been instrumental in developing new treatment methodologies and advancing pharmaceutical research.

Collaborations. Throughout his career, Joshua Hansen has collaborated with esteemed colleagues, including Matthew Daniel Correa and Matthew David Alexander. These partnerships have facilitated the fusion of creative ideas and expertise, driving the development of cutting-edge therapeutic solutions.

Conclusion. In conclusion, Joshua Hansen stands out as a prominent inventor in the pharmaceutical field. His numerous patents reflect a commitment to innovation and a profound understanding of biological treatments. As he continues to work towards advancing medical science, his contributions will undoubtedly shape the future of therapeutic development.

This text is generated by artificial intelligence and may not be accurate.